Stock Market Reviews

THAR (Tharimmune, Inc.) News

Get the latest news, insights, and market updates on THAR (Tharimmune, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
  RED BANK, NJ / ACCESS Newswire / August 5, 2025 / Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical ...
  Aug 5, 2025 - $THAR
• Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
  -Company closes approximately $5.47 million in equity financing in 2Q/3Q25-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl- TH023 may fulfill the promise of delivering a safe and effective oral antibody medication ...
  Aug 4, 2025 - $THAR
• Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants
  RED BANK, NJ / ACCESS Newswire / July 23, 2025 / Tharimmune, Inc. (the "Company" and "Tharimmune") (Nasdaq Capital Market:THAR), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced ...
  Jul 24, 2025 - $THAR
• Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
  BRIDGEWATER, NEW JERSEY / ACCESS Newswire / June 17, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, today announced significant appointments ...
  Jun 17, 2025 - $THAR
• Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
  BRIDGEWATER, NJ / ACCESS Newswire / May 19, 2025 / Tharimmune, Inc. (Nasdaq:THAR), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics, today announced the appointment of James Gordon Liddy (CDR US Navy SEAL (Ret)) ...
  May 19, 2025 - $THAR
• Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
  BRIDGEWATER, NEW JERSEY / ACCESS Newswire / May 6, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology released ...
  May 6, 2025 - $THAR
• Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
  BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced abstracts ...
  May 1, 2025 - $THAR
• Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
  BRIDGEWATER, NJ / ACCESS Newswire / April 30, 2025 / Tharimmune, Inc., (NASDAQ:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced ...
  Apr 30, 2025 - $THAR
• Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
  BRIDGEWATER, NJ / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced ...
  Apr 28, 2025 - $THAR
• Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
  BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas ...
  Apr 15, 2025 - $THAR